Eli Lilly and Co (LLY) : Rodgers Brothers reduced its stake in Eli Lilly and Co by 0.25% during the most recent quarter end. The investment management company now holds a total of 80,243 shares of Eli Lilly and Co which is valued at $6,437,093 after selling 200 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Eli Lilly and Co makes up approximately 2.63% of Rodgers Brothers’s portfolio.
Other Hedge Funds, Including , Causeway Capital Management boosted its stake in LLY in the latest quarter, The investment management firm added 609,341 additional shares and now holds a total of 2,232,925 shares of Eli Lilly and Co which is valued at $179,125,244. Eli Lilly and Co makes up approx 3.63% of Causeway Capital Management’s portfolio.Massachusetts Financial Services Co boosted its stake in LLY in the latest quarter, The investment management firm added 715,620 additional shares and now holds a total of 11,913,007 shares of Eli Lilly and Co which is valued at $955,661,422. Eli Lilly and Co makes up approx 0.46% of Massachusetts Financial Services Co’s portfolio.
Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.